Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.

With its multiple sclerosis legacy under various pressures but four new drugs in indications outside of MS, the company expects flat product revenue in 2024 after a 3.8% decline in 2023.

Friedreich’s ataxia is particularly prevalent in Europe, and the company hopes to replicate the fast US uptake for Skyclarys there.

Priya Singhal, head of development, spoke with Scrip about the company’s R&D restructuring, readouts coming from the culled pipeline and how Biogen is thinking about adding to it in the future.